Open Orphan - ORPH Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0
+0 (0.00%)

This chart shows the closing price for ORPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Open Orphan Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORPH

Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for Open Orphan in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.

This chart shows the closing price for ORPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Open Orphan. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/28/2020FinnCapReiterated RatingCorporate
7/7/2020FinnCapReiterated RatingCorporate
6/24/2020FinnCapReiterated RatingCorporate
6/11/2020FinnCapReiterated RatingCorporate
5/26/2020FinnCapInitiated CoverageCorporateGBX 19
(Data available from 12/23/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/26/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/26/2024
  • 3 very positive mentions
  • 34 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
8/25/2024
  • 3 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 7 very negative mentions
9/24/2024
  • 7 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
10/24/2024
  • 5 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
11/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Open Orphan logo
Open Orphan Plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: N/A

50 Day Range

MA: GBX 10
Low: 10
High: 10

52 Week Range

Now: N/A

Volume

652,639 shs

Average Volume

1,559,247 shs

Market Capitalization

£67.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Open Orphan?

The following Wall Street analysts have issued reports on Open Orphan in the last twelve months:
View the latest analyst ratings for ORPH.

What is the current price target for Open Orphan?

0 Wall Street analysts have set twelve-month price targets for Open Orphan in the last year. has the lowest price target set, forecasting a price of £100,000 for Open Orphan in the next year.
View the latest price targets for ORPH.

What is the current consensus analyst rating for Open Orphan?

Open Orphan currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ORPH.

What other companies compete with Open Orphan?

How do I contact Open Orphan's investor relations team?

Open Orphan's physical mailing address is Ole Maaloees Vej 3, Copenhagen N, Koebenhavn 2200. The company's listed phone number is 353 1 644 0007. The official website for Open Orphan is www.openorphan.com. Learn More about contacing Open Orphan investor relations.